Capricor Therapeutics, Inc.
CAPR
NASDAQ·Healthcare·Biotechnology·Mkt cap $540.6M
$9.40
▲ +1.29%
P/E
-3.84
Mkt Cap
$540.6M
52-Wk Range
$2.96–$40.37
52-Week Range
$2.96 - $40.37
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 48.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary allogeneic cardiac-derived cell therapy platform with Phase III clinical validation
- Established manufacturing partnerships with Lonza for scalable production and commercialization
- Diversified pipeline addressing multiple high-value indications with significant unmet medical needs
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Phase III trial completion for CAP-1002 in DMD with potential regulatory approval pathway
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-64.1% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CAPR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 13, 2026
Reported EPS of -$0.70 vs -$0.59 consensus (-18.9% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-18.9%
Revenue trend · last 8Q
—
-8%
-100%
-100%
-100%
-100%
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.3M
$11.1M
$0
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
7 analysts · 29% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
29%
Hold
71%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Sep 1, 2026
vs Industry
How CAPR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related